GalleonBio is a mid-stage biopharmaceutical company focusing on the development of novel topical therapies for the management of inflammatory dermatological, neuropathic pain and other conditions.

Based on multiple years of research and scientific innovation in rare earth metals, GalleonBio’s scientists have developed a unique therapeutic technology platform of products containing strontium.

Using this platform, GalleonBio has created a range of proprietary novel topical compounds. Their 1^st compound (GB100) has completed Phase I trials and is ready to start Phase II